Company intelligence / Profile preview

Biogemma

Paris, Île-de-France, France

Ownership: Private
Employees: ~80
Development stage: Other

Overview

Biogemma has developed and validated genetically engineered traits in maize and wheat for commercial deregulation and leads programs in genomics-enabled marker development for improved field crops, publicly advancing programs for yield and drought tolerance in corn

Therapeutic areas: Infectious DiseasesOtherMetabolic Disorders
Modalities: Genetic engineeringTransgenic plantsMarker-assisted breeding
Industry: Agriculture & AgTech

Partnerships

EvogeneRoche NimbleGen

Beyond the preview

Go deeper on Biogemma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biogemma.

Explore the full profile